Tata India Pharma & Healthcare Growth Direct Plan
SIP amount
Min. ₹100
Lumpsum amount
Min. ₹5,000

Tata India Pharma & Healthcare Growth Direct Plan

NAV
₹33.8586
-1.90%
(25 Apr)
AUM
1,184 Cr
TER
0.72%
Risk
Very High Risk
Insights
Net Asset Value (NAV) is below its 200 days moving average
In beta. Send feedback here.
Compare with other fund
1Y
+18.3%
+11.3%
+0.7%
-0.0%
-6.1%
3Y
+22.1%
+30.6%
+30.6%
+32.2%
+29.5%
5Y
+23.5%
+33.9%
+30.9%
+32.8%
+34.5%
ALL
+14.0%
+18.1%
+16.7%
+11.9%
+26.0%
VOL
15.8%
16.4%
19.9%
20.4%
22.8%
TER
0.7%
0.6%
0.9%
0.8%
0.5%
AUM
₹1,184 Cr
₹6,047 Cr
₹1,217 Cr
₹4,789 Cr
₹5,342 Cr
INFO
0.89
1.10
0.84
0.58
1.14
Past performance
Past performance is no guarantee of future returns.
Had you invested
Over the last
1Y
3Y
ALL
Your returns would have been
Tata India Pharma & Healthcare (G)
₹1,00,00,00,000
14.0%
Fixed deposit
₹40,00,00,000
6.0%
Bank savings
₹40,00,00,000
3.0%
See fund holdings as of 31st Mar
Top holdings
Sun Pharmaceuticals Industries Ltd
11.8%
Aurobindo Pharma Ltd
7.3%
Cipla Ltd
6.0%
Apollo Hospitals Enterprise Ltd
5.7%
Lupin Ltd
5.2%
Divi's Laboratories Ltd
5.1%
Fortis Healthcare Ltd
5.0%
Cash / Net Current Asset
4.0%
Aster DM Healthcare Ltd Ordinary Shares
3.9%
Dr Reddy's Laboratories Ltd
3.5%
Top industry exposure
Healthcare
93.4%
Basic Materials
2.3%
Other information
Minimum SIP
₹100
Minimum lumpsum
₹5,000
Additional lumpsum
₹1,000
Portfolio turnover
12%
Lock-in period
-
Exit load
• 0.25% for redemption within 30 days
Fund objective
The investment objective of the scheme is to seek long term capital appreciation by investing atleast 80% of its net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.
Fund manager(s)
Meeta Shetty
Rajat Srivastava

FAQs